Traws Pharma, Inc. (TRAW) Stock: Price, Forecast & Analyst Target
Traws Pharma, Inc. (TRAW) — MoonshotScore 30/100 (Weak band), calculated Nov 18, 2026. Price $0.2425 (+3.94%), as of the Nov 18, 2026 trading session; market cap $3.73M.
Educational signal · not a buy or sell recommendation · How to read this
Traws Pharma, Inc. · TRAW · NASDAQ
Traws Pharma, Inc.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Traws Pharma (TRAW)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Durable growth, but a fragile balance sheet and an expensive valuation, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Solid; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Compounding; Momentum: Falling.
Earnings yield is the main valuation drag relative to sector peers.
- quarterly revenue $3M (Q2 FY2025, quarter ended Jun 2025)
- EPS beat 0 of the last 4 reports
Holding back: balance-sheet strain, a rich price, weak price trend
Helping: durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 30 | Weak | |
| 30 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.2425 | |
| Change on the day | +3.94% | |
| 52-week range | $0.2187 – $3.23 | |
| Market capitalisation | $3.73M | — |
| Shares traded on the day | 213.8K |
Price & events
Other perspectives
Council score for Traws Pharma (TRAW): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Three of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Englander-style lens and Moon AI lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Traws Pharma (TRAW), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Traws Pharma, Inc. (TRAW) is listed on NASDAQ. It employs 7 people and is led by Iain D. Dukes. In Q2 FY2025 it reported revenue of $3M and net income of -$915,000. The market values it at $3.73M.
What do the latest results show for Traws Pharma (TRAW)?
Short answer · as of
The most recent reported quarter, Q2 FY2025, carried revenue of $3M. Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Quarterly income statement — 1 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2025 | $3M | -$915,000 | -$0.11 (diluted) |
What are the financial strengths and risks for Traws Pharma (TRAW)?
Short answer
The MoonshotScore pillars rate durable growth as strengths. What is holding it back is balance-sheet strain, a rich price, weak price trend. The distress and quality screens read Piotroski F 1. Trailing ratios: current ratio 0.52.
Data-derived red flags
- Listing risk — at $0.2425 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What should you watch next at Traws Pharma (TRAW)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $300,000 · EPS -1.20 · 2 analysts. Current published price targets run low $1.00 · high $1.00 · consensus $1.00 · median $1.00 against a quoted price of $0.2425 (as of Nov 18, 2026).
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- The newest quarter held here (Q2 FY2025) was filed Aug 14, 2025 — 15 months ago.
Checked against the records this page reads, on the dates shown above.
How does Traws Pharma compare with its peers?
Short answer
Traws Pharma's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $3.02 Nov 18, 2026 | $255M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.96 Nov 18, 2026 | $186M | 69 5-pillar Nov 18, 2026 | |
| $12.48 Nov 18, 2026 | $884M | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $29.68 Nov 18, 2026 | $993M | 64 5-pillar Nov 18, 2026 | |
| $8.32 Nov 18, 2026 | $813M | 63 5-pillar Nov 18, 2026 | |
| Traws Pharma (TRAW) — this page | $0.2425 | $3.73M | 30 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $1.00 – $1.00
- Consensus target
- $1.00
- Median target
- $1.00
- Revenue estimate
- $300,000
- EPS estimate
- $-1.20
Consensus record · Captured .
Measured against a quoted price of $0.2425 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jul 9, 2026
- Transactions
- 10
- Identified insiders
- 10
- Purchases
- 0
- Sales
- 0
- Other transactions
- 10
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held TRAW in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported TRAW in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Investor Questions: TRAW Stock
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for TRAW?
TRAW carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is TRAW a good stock to buy?
Stock Expert AI does not rate TRAW buy, sell or hold. Traws Pharma, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the TRAW stock price today?
The last price recorded for Traws Pharma, Inc. (TRAW), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the TRAW price target?
The analyst consensus price target for Traws Pharma, Inc. (TRAW), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the key factors to evaluate for TRAW?
Traws Pharma, Inc. (TRAW) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Dividend Yield: None, as the company is in a clinical development phase and does not currently distribute dividends. Not financial advice.
How frequently does TRAW data refresh on this page?
TRAW's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven TRAW's recent stock price performance?
Traws Pharma, Inc. (TRAW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse pipeline targeting significant unmet medical needs in respiratory viral infections and oncology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TRAW overvalued or undervalued right now?
Traws Pharma, Inc. (TRAW) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of TRAW?
Fractional-share availability for Traws Pharma, Inc. (TRAW) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 24 figures on this page — 13 from Financial Modeling Prep (FMP), 9 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com